louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04598971: Urine pH and Urinary Tract Infection
Official title: Consequences of UTI on Urine pH
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Urinary Tract Infections
Urinary Stone
Keywords: urine pH
Lead sponsor: Centre Hospitalier Universitaire Vaudois
Sponsor class: OTHER
First posted: 2020-10-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patient consulting the primary care unit of the medical outpatient clinic UniSanté in Lausanne will be asked to participate.

Brief summary: Urinary tract infections (UTI) affect the urine pH and may lead to salt precipitation such as struvite. Bacteria with urease activity are known to alkalinise urine, but not much is known on how pH is changing over time during UTI.

This study aims at following urine pH progression at the time of diagnosis of UTI and during the treatment phase.

Description of the change in urine pH over time will help understanding the risk of struvite formation and potential timing of intervention.

Detailed description: Adults presenting with UTI symptoms will be screened for infection and instructed to monitor urine pH during the course of treatment and 1 week after. Urine pH will be measured by the patients using calibrated pH-stix. Type of bacteria, antibiotics, and the type of diet will be monitored during the study.

Eligibility criteria: Group 1. Cystitis

Inclusion Criteria:

* Symptoms of dysuria, pollakiuria, no fever AND
* urine-stix positive for leucocytes OR positive culture (\>10E5 cfu/ml)

Group 2. Pyelonephritis

Inclusion Criteria:

* Unilateral flank pain, pollakiuria, dysuria, fever (\>38.5°C) AND
* urine-stix positive for leucocytes OR positive culture (\>10E5 cfu/ml)

Exclusion Criteria (both groups):

* known urinary tract anatomic abnormalities
* Presence of a urine catheter
* Sepsis - septic shock
* Patient taking drug interfering with urine pH (diuretics, citrate, acetazolamide, topiramate,...)
* Patients with UTI diagnosed in the preceding month
* Patients having received antibiotics during the preceding month
* Male patient with a diagnosis of prostatitis
* Presence of infected kidney cyst
* Patient with diabetes
* Pregnant female
* Patient with obstructive pyelonephritis

Primary outcomes:
measure: Urine pH
timeFrame: 21 days
Secondary outcomes:
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: UniSanté
state: VD
Study officials:
affiliation: CHUV-Lausanne
name: Olivier Bonny, MD-PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04396171: Association of Probable Bruxism With Periodontal Status
Official title: Association of Probable Bruxism With Periodontal Status: A Cross Sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bruxism
Lead sponsor: Baskent University
Sponsor class: OTHER
First posted: 2020-05-20
Enrollment: 541
Sex: ALL
Minimum age (years): 18
Maximum age (years): 82
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patients who applied to Department of Periodontology, Baskent University were included into the study.

Brief summary: This cross-sectional study was conducted to assess i) the prevalence of probable bruxism ii) the association between probable bruxism and periodontal status.The age, gender, education level, tooth loss, presence of probable bruxism and periodontal status of patients were evaluated. Periodontal statuses of the participants were defined according to the American Association of Periodontology/European Federation of Periodontology, 2017 consensus and assessment of probable bruxism was performed according to the 2018 consensus report on the assessment of bruxism.

Detailed description: This cross-sectional study was conducted to assess i) the prevalence of probable bruxism ii) the association between probable bruxism and periodontal status dental examination, all participants completed a standardized questionnaire. Sociodemographic findings comprised age, gender and educational level. Periodontal statuses of the participants were defined according to the American Association of Periodontology/European Federation of Periodontology, 2017 consensus. Participants were diagnosed with periodontitis if interdental clinical attachment loss (AL) was detected at ≥2 non-adjacent teeth, or buccal or oral AL was ≥3 mm with probing depth \>3 mm was detected at ≥2 teeth. 12 In addition number of missing teeth is recorded.Assessment of probable bruxism was performed according to the 2018 consensus report on the assessment of bruxism.Presence of masticatory muscle hypertrophy, temporomandibular joint pain, indentations on the tongue or lip and/or a linea alba on the inner cheek, damage to the dental hard tissues (eg, cracked teeth), mechanical wear of the teeth (ie, attrition), repetive failures of restorative work/prosthodontics constructions were examined in clinical evaluation.

Eligibility criteria: Inclusion Criteria:

* Patients with 18 years and older

Exclusion Criteria:

* age under 18 years,
* edentulous patients,
* not interested to participate in this study.

Primary outcomes:
measure: probable bruxism
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Baskent University,Department of Dentistry
Study officials:
References:
Clinical trial NCT03180671: Anterior Deprogrammers for Reducing Pain and Masticatory Muscles Tension
Official title: The Effectiveness of Anterior Deprogrammers as a Tool for Reducing Pain and Masticatory Muscles Tension
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Temporomandibular Disorders
Keywords: anterior deprogrammer
muscle pain
centric relation
Lead sponsor: Wroclaw Medical University
Sponsor class: OTHER
First posted: 2017-06-08
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: The study will be conducted in four groups of 20 patients in age of 20-30 years with complete dentition or single tooth loss in lateral regions, with masticatory muscle pain in the history or during examination and overuse and/or chronic tensing of the masticatory muscles. Patients will be randomly assigned to the groups.

Each person will be measured twice before and after use of selected anterior deprogrammer. The following assessment tools will be applied:

* surface electromyography of masseter and temporal muscles,
* intraoral pin-supported registration to draw a gothic arch.

Measurements will be made before and after intervention to assess the effect of anterior deprogrammer application on the tone of the selected masticatory muscles and condyles position in mandibular fossa. The first group (control) will be counsel with an explanation of the pathomechanism of masticatory muscles pain and preventive principles. In the second group, the Sliding Guide will be used for a period of 12-15 minutes, in the third Dawson B-Splint for 7 days, and in the fourth Kois deprogrammer for 14 days. Devices in group 3 and 4 will be used by patients for 24 hours a day, with breaks for oral hygiene procedures and eating/drinking.

The aim of the study is to evaluate the effectiveness of selected anterior deprogrammers.


Eligibility criteria: Inclusion Criteria:

* age 20-30 years old
* complete dentition or single tooth loss in the lateral regions
* no severe systemic diseases
* masticatory muscle pain in the history or during examination
* increased masticatory muscles tension

Primary outcomes:
measure: Electromyography
timeFrame: 2 min
Secondary outcomes:
measure: Centric relation
timeFrame: 5 min
Other outcomes:
Locations:
city: Tarnow
country: Poland
facility: Dental Practice
Study officials:
affiliation: Wroclaw Medical University
name: Mieszko Wieckiewicz, DMD, MSc, PhD
role: STUDY_CHAIR
affiliation: Dental Practice
name: Lukasz Adamczyk, DMD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06935071: Endoprosthetic Replacement for Pathological Fractures of the Hip: A 35-year Update
Official title: Endoprosthetic Replacement for Pathological Fractures of the Hip: A 35-year Update
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Hip Fractures
Hip Fracture Pathologic
Pathological Fracture
Pathological Fracture of Hip
Keywords: hip fractures
pathological hip fractures
hip fracture parthologic
pathological fracture of hip
16-1122
Memorial Sloan Kettering Cancer Center
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2025-04-18
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: For this retrospective data review, the study team will query the orthopaedic caisis database and IDB to obtain a list of all participants who have received endoprosthetic reconstruction for pathologic fracture of the proximal femur.

Brief summary: This study will be based on a retrospective review of patients who received endoprosthetic reconstruction for pathologic fracture of the proximal femur. The objectives would be two-fold: (1) to compare rates ofambulation, pain, and survival to the historic cohort and (2) to identify predictors of ambulation in the current population.


Eligibility criteria: Inclusion Criteria:

* Participants have received endoprosthetic reconstruction for pathologic fracture of the proximal femur

Exclusion Criteria:

* Participants with fractures greater than 3mm from the lesser trochanter
* Participants without histopathologic confirmation of tumor

Primary outcomes:
measure: Comparison of rates of ambulation, pain, and survival to the historic cohort
timeFrame: up to 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: John Healey, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04786171: 4D Medical X-ray Velocimetry for Bronchoscopic Lung Volume Reduction Targeting
Official title: 4DXV for Targeting in Bronchoscopic Lung Volume Reduction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Copd
Emphysema
Hyperinflation
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
Collaborators: name: American Thoracic Society
First posted: 2021-03-08
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults with symptomatic emphysema with hyperinflation and no conflating lung diseases or pregnancy.

Brief summary: This study will investigate the utility of 4D Medical's X-ray Velocimetry (XV) imaging analysis software for the detection of hyperinflation, and compare endobronchial valve placement outcomes with predictive indices obtained utilizing this technique.


Eligibility criteria: Inclusion:

* CT chest and PFTs within the last two years
* Age over 18
* COPD with emphysema
* Global Initiative for Chronic Obstructive Lung Disease (GOLD) 3 - 4 classification OR modified Medical Research Council (mMRC) score of 2 or greater.

Exclusion Criteria:

* Pregnancy
* Presence of an additional pulmonary disease beyond COPD
* Inability to raise arms above 90 degrees as required for fluoroscopy

Primary outcomes:
measure: Ratio of residual volume over functional residual capacity by 4DXV
timeFrame: 6 months
measure: Expiratory Time Constants vs Fissure Completeness
timeFrame: 1 year
Secondary outcomes:
measure: Improvement in Saint George Respiratory Questionnaire (SGRQ)
timeFrame: 1 year
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
References:
Clinical trial NCT00263471: Myopia Progression and the Effect of 7-Methylxanthine
Official title: Phase 2 Study of the Effect of 7-Methylxanthine on the Progression of Childhood Myopia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Myopia
Lead sponsor: Trier Research Laboratories
Sponsor class: OTHER
Collaborators: name: Generalkonsul Einar Høyvalds Fond
name: Jørgen Bagenkop Nielsens Myopi-Fond
name: Chr. Andersen og hustru Ingeborg Andersen, f. Schmidts legat (fond) oprettet af deres datter, frk. Lilli Ellen Andersen.
First posted: 2005-12-08
Enrollment: 90
Sex: ALL
Minimum age (years): 8
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: 7-methylxanthine has been shown to increase the concentration and thickness of collagen fibrils in rabbit sclera. Deficient collagen in the sclera may be the cause of progression of childhood myopia. The study hypothesis is that treatment with 7-methylxanthine will stabilize the sclera and prevent further progression of myopia.

Detailed description: Participants are given tablets of 7-methylxanthine 400 mg per day or placebo tablets for 12 months. Axial length, cycloplegic refraction and corneal curvature is measured, as well as weight, height, blood pressure and heart rate. The participants are interviewed about possible CNS, gastrointestinal, or cardiopulmonal side effects.

Eligibility criteria: Inclusion Criteria:

Children in the age 8-13 years with myopia and an axial growth rate of 0.15 mm or more per year.

-

Exclusion Criteria:

Severe general ailment (for example diabetes, epilepsy, psychiatric disease) Eye diseases (for example cataract, keratoconus, chronic iritis, glaucoma)

-

Primary outcomes:
measure: Axial growth
Secondary outcomes:
measure: Myopia progression
Other outcomes:
Locations:
Study officials:
affiliation: Trier Research Laboratories
name: Klaus Trier, MD
role: STUDY_CHAIR
References:
citation: Trier K, Olsen EB, Kobayashi T, Ribel-Madsen SM. Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or L-ornithine. Br J Ophthalmol. 1999 Dec;83(12):1370-5. doi: 10.1136/bjo.83.12.1370.
citation: Cui D, Trier K, Munk Ribel-Madsen S. Effect of day length on eye growth, myopia progression, and change of corneal power in myopic children. Ophthalmology. 2013 May;120(5):1074-9. doi: 10.1016/j.ophtha.2012.10.022. Epub 2013 Feb 4.
Clinical trial NCT00632671: COLOMBES Project:Constitution of a Population-based Cohort of Obese Subjects With Longitudinal Long-term Follow-up
Official title: Constitution of a Population-based Cohort of Obese Subjects With Longitudinal Long-term Follow-up.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Obesity
Keywords: Obesity cohort
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2008-03-11
Enrollment: 311
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Morbidly obese subjects

Brief summary: The objective of the project is the constitution of a population-based cohort of 500 persons with severe or morbid obesity (BMI over 35 kg/m2) with annual follow-up for 10 years. It aims to improve the physiopathological, epidemiological and prognostic knowledge of obesity and its consequences. Clinical data, biological material, exams and questionaires will be collected and stored, allowing the realisation of research works, initiated by research teams from our hospital or from other settings.

Detailed description: The objective of this observational study is the follow-up of a cohort of 500 adult persons with morbid obesity (BMI\>35 kg/m2).

Clinical and paraclinical data, and biological samples (plasma, serum, DNA, RNA, cell blood, for persons undergoing bariatric surgery (specific consent): samples of liver and adipocytes) will be collected and stored during the follow-up visits. These visits take place at inclusion, at 6 months, twelve months and every year for ten years. The collection of parental DNA will be proposed when feasable for genetic studies.

Persons will be recruited for four years, with an expected number of 350 persons included, in the clinical research unit of Louis MOURIER university hospital (AP-HP).

Each person included will participate in the study for ten years. When included, patients agree to come every year to follow-up visits. They are informed that data collected will be used only for research on obesity and its health consequences.

Eligibility criteria: Inclusion Criteria:

* BMI\>35

Exclusion Criteria:

* previous bariatric surgery
* pregnancy

Primary outcomes:
measure: Rate of follow-up at annual visit
timeFrame: annual
Secondary outcomes:
measure: Assessment of knee arthrosis (pain and radiological exam), at inclusion and after loss-weight (comparison after one and two years of follow-up of patients that did or did not undergo bariatric surgery).
timeFrame: one and two years of follow-up
Other outcomes:
Locations:
city: Colombes
country: France
facility: Louis Mourier hospital (AP-HP)
Study officials:
affiliation: Louis Mourier University Hospital (AP-HP)
name: Simon Msika, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05953571: Laparoscopic Assisted Dismembered Pyeloplasty Versus Open Pyeloplasty in (UPJO) With Poorly Function Kidney in Pediatrics
Official title: Laparoscopic Assisted Dismembered Pyeloplasty Versus Open Pyeloplasty in (UPJO) With Poorly Function Kidney in Pediatrics
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Uretro-pelvic Junction Obstruction
Poorly Function Kidney
Keywords: UPJO
Poorly function kidney
Laparoscopic assissted pyeloplasty
Open pyeloplasty
Pediatrics
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
Collaborators: name: University Hospital Fattouma Bourguiba
First posted: 2023-07-20
Enrollment: 65
Sex: ALL
Minimum age (years): 2
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children suffered from Uretro-pelvic junction obstruction with split renal function less than 10%

Brief summary: The management of kidneys with poor function less than 10% has been the subject of debate for more than a decade. Some authors have recommended nephrectomy while others favor renal salvage (pyeloplasty). the investigators reported their experience of lap assisted pyeloplasty in poorly functioning kidneys in the pediatric age group, concerning on the benefits of a minimally invasive method for repair of UPJO, in comparison with open approach.


Eligibility criteria: Inclusion Criteria:

* Patients with hydronephrosis diagnosed as UPJO
* Antero-Posterior pelvic diameter more than 20 mm
* renal function equal or less than 10%,
* corrected by laparoscopic assisted or open pyeloplasty

Exclusion Criteria:

* Patients with ureteral dilatation (VUR),
* renal function more than 10%,
* acquired and recurrent cases

Primary outcomes:
measure: Renal function
timeFrame: 12 months post-operative
measure: Measurments A-P renal pelvis diameter
timeFrame: 12 months
Secondary outcomes:
measure: operative time
timeFrame: one month
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Mohammad Daboos
state: Select
Study officials:
References:
Clinical trial NCT00693771: Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
Official title: A Prospective Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2008-06-09
Enrollment: 313
Sex: ALL
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Primary objective:

To show an improvement in HbA1c control after 4 months of treatment with insulin glargine + Oral Anti Diabetic (OAD) in patients previously uncontrolled on premixed insulin (with OAD)

Secondary objective:

Improvement of Fasting blood glucose (FPG) after 4 months treatment (% of patients treated to target HbA1c ≤7.0% and/or FBG≤6.0mmol/L). Frequency of hypoglycemic episodes, quality of life with basal+ OAD regimen.


Eligibility criteria: Inclusion Criteria:

* Patients with Type 2 Diabetes Mellitus inadequately controlled at least 3 months on premixed insulin with 1 or 2 OADs
* 7.5 ≤ HbA1c ≤ 9.5%
* FPG ≥6.7 mmol/L
* History of Diabetes mellitus ≤10 years
* Premix insulin daily dosage ≤ 50 IU/Day

Exclusion Criteria:

* Type 1 Diabetes Mellitus
* Former treated on TZD
* Pregnancy / Lactation
* Creatine ≥1.5 mg/dl
* Hepatic disease, jaundice,or ALT/AST≥ 2.5 times of normal range
* Hormone therapy,
* Acute status of Diabetes complications
* Severe concomitant disease or complications with high risk of unexpected fatal events, like Myocardial Infarct, stroke, heart failure.
* Allergic to insulin glargine or any ingredient
* Participation in another clinical trial within 3 months

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: HbA1c values
timeFrame: At baseline and 16 weeks
Secondary outcomes:
measure: Adverse events including hypoglycemia
timeFrame: From the beginning to the end of the study
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: Rui Yan Ding
role: STUDY_DIRECTOR
References: